gms | German Medical Science

21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem
8. Symposium der International Society of Ocular Trauma

Deutsche Gesellschaft für Retinologie
International Society of Ocular Trauma

19.06. - 22.06.2008, Würzburg

Artikel

Artikel empfehlen

Photodynamic Therapy with Verteporfin combined with Intravitreal Injection of Ranibizumab for Occult and Classic CNV in AMD

Meeting Abstract

Suche in Medline nach

  • Mathias Maier - München/Germany
  • N. Feucht - München/Germany
  • B. Fiore - München/Germany
  • C. Winkler - München/Germany
  • C. von Mohrenfels - München/Germany
  • P. Kook - München/Germany
  • C. Fegert - München/Germany
  • C.P. Lohmann - München/Germany

Retinologische Gesellschaft. International Society of Ocular Trauma. 21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem 8. Symposium der International Society of Ocular Trauma. Würzburg, 19.-22.06.2008. Düsseldorf: German Medical Science GMS Publishing House; 2008. DocISOTRG2008V120

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/rg2008/08rg121.shtml

Veröffentlicht: 18. Juni 2008

© 2008 Maier et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.

Gliederung

Text

Purpose: To discuss the effect and outcome of a combined photodynamic therapy and intravitreal injection of ranibizumab (0.5 mg) in occult CNV with recent disease progression and in classic choroidal neovascularisation (CNV) due to AMD.

Methods: In a pilot study in 25 patients (18 classic, 7 occult CNV) intravitreal injection of ranibizumab was administered within 12 to 24 hours after standard PDT , followed by 2 injections of ranibizumab after 1 and 2 months. Before, 3 and 6 month after treatment visual acuity, OCT examinations (retinal thickness) and fluorescein angiography were performed.

Results: Mean visual acuity was significantly improved compared to baseline. (VA baseline 20/80, after 3 month 20/50, and 20/63 after 6 month). We found no choroidal hypoperfusion and no RPE rip. OCT-findings and fluorescein angiography in patients with occult and classic choroidal neovascularisation 3 and 6 month after combination therapy showed a reduced retinal thickness (baseline: 241µm, after 3 month: 205µm and after 6 month 232µm) and reduction of leakage compared to baseline.

Conclusions: Photodynamic therapy combined with injection of intravitreal ranibizumab was well tolerated and tends to be more effective compared to ranibizumab mono-therapy. Our short term results are very promising. Further studies are necessary to show the long term effect of PDT and Anti-VEGF combination therapy.